CAJ | 학술논문

目的：观察瑞舒伐他汀治疗急性冠状动脉综合征（ACS）患者的治疗效果以及高敏 C-反应蛋白（hs-CRP）水平。方法选择广东医学院附属医院和解放军92854部队医院收治的 ACS 患者207例，将其随机分为辛伐他汀组（65例）、10 mg 瑞舒伐他汀组（67例）和20 mg 瑞舒伐他汀组（75例），在常规治疗的基础上，分别观察服药2、4周的 hs-CRP 水平。结果三组服药前 hs-CRP 水平分别为（12.5±2.4）、（12.4±2.3）、（12.2±2.5）mg/ L，差异无统计学意义（ P >0.05）。三组患者服药2周后血清 hs-CRP 明显降低（P <0.05），分别为（10.6±2.5）、（9.9±2.4）、（8.6±2.3）mg/ L，但三组间比较差异无统计学意义（P >0.05）；服药4周后，20 mg 瑞舒伐他汀组 hs-CRP 较辛伐他汀组及10 mg 瑞舒伐他汀组 hs-CRP 浓度降低更明显，差异有统计学意义（P <0.05）。结论瑞舒伐他汀治疗可使 ACS 患者的 hs-CRP 水平明显降低，且高剂量瑞舒伐他汀抗炎效果更显著。
목적：관찰서서벌타정치료급성관상동맥종합정（ACS）환자적치료효과이급고민 C-반응단백（hs-CRP）수평。방법선택엄동의학원부속의원화해방군92854부대의원수치적 ACS 환자207례，장기수궤분위신벌타정조（65례）、10 mg 서서벌타정조（67례）화20 mg 서서벌타정조（75례），재상규치료적기출상，분별관찰복약2、4주적 hs-CRP 수평。결과삼조복약전 hs-CRP 수평분별위（12.5±2.4）、（12.4±2.3）、（12.2±2.5）mg/ L，차이무통계학의의（ P >0.05）。삼조환자복약2주후혈청 hs-CRP 명현강저（P <0.05），분별위（10.6±2.5）、（9.9±2.4）、（8.6±2.3）mg/ L，단삼조간비교차이무통계학의의（P >0.05）；복약4주후，20 mg 서서벌타정조 hs-CRP 교신벌타정조급10 mg 서서벌타정조 hs-CRP 농도강저경명현，차이유통계학의의（P <0.05）。결론서서벌타정치료가사 ACS 환자적 hs-CRP 수평명현강저，차고제량서서벌타정항염효과경현저。
Objective To evaluate the effect of rosuvastatin on patients with acute coronary syndrome(ACS)and the change of levels of high-sensitive C-reactive protein(hs-CRP). Methods Two hundred and seven patients with ACS of Guangdong Medical College affiliated hospital and 92003 Army Health Care Clinics of PLA were selected randomly divided into three groups:simvastatin treatment group(n = 65),10 mg rosuvastatin treatment group(n = 67)and 20 mg rosuvastatin treatment group(n =75). Based on routine treatment,simvastatin or rosuvastatin were added,and the levels of hs-CRP were observed after 2 weeks and 4 weeks treatment. Results The differences of the hs-CRP levels among the three groups before treatment were not signifi-cant(P > 0. 05),which were(12. 5 ± 2. 4),(12. 4 ± 2. 3)and(12. 2 ± 2. 5)mg/ L respectively. After added simvastatin or rosuv-astatin for 2 weeks,the level of hs-CRP significantly reduced(P < 0. 05),(10. 6 ± 2. 5),(9. 9 ± 2. 4)and(8. 6 ± 2. 3)mg/ L re-spectively,but there were no significant differences among the three groups. After added simvastatin or rosuvastatin for 4 weeks, the hs-CRP level of the 20 mg rosuvastatin groups were significantly lower than the others(P < 0. 05). Conclusion Treatment with high does rosuvastatin(20 mg)can reduce the hs-CRP level,and improve the function of the vascular endothelium,which may promote the stabilization of atherosclerotic plaque.